TLDR
-
uniQure stock dropped about 45% after the FDA rejected its proposed approval pathway for AMT-130.
-
The regulator said early and mid-stage trial data were not sufficient to support a marketing application.
-
The FDA recommended a new randomized, controlled study before any potential approval submission.
-
uniQure plans to request another FDA meeting in Q2 2026 to discuss Phase III trial design.
-
The setback could delay timelines for the Huntington’s disease gene therapy program.
uniQure (QURE) stock moved sharply lower after the U.S. Food and Drug Administration rejected its proposed approval pathway for AMT-130. The regulatory update triggered a steep decline in early trading.
The FDA said data from Phase I/II studies were not sufficient to support a marketing application. The agency concluded that comparisons with external controls did not meet requirements for primary evidence of effectiveness.
The feedback followed a Type A meeting held on January 30. Final meeting minutes confirmed the regulator’s position on the proposed submission pathway.
The FDA recommended that uniQure conduct a prospective, randomized, double-blind study. The suggested trial would include a sham surgery control group to generate additional evidence.
uniQure said it plans to continue discussions with the FDA regarding development of AMT-130. The company intends to request a Type B meeting in the second quarter of 2026 to discuss future trial design.
Regulatory Setback and Development Timeline
The FDA decision represents a delay for the company’s development timeline. uniQure had planned to seek marketing approval for AMT-130 in early 2026.
The gene therapy is being developed for Huntington’s disease. The inherited neurological disorder causes progressive degeneration of nerve cells in the brain.
There are currently no approved treatments that slow the progression of the disease. uniQure had hoped early and mid-stage data would support a regulatory filing.
Previous study results showed reductions in disease progression over a three-year period using clinical measurement scales. Despite these findings, the FDA said further controlled data are required.
A new randomized trial would require additional time and resources. This could push back any potential regulatory submission and launch timeline.
Next Steps and Company Response
uniQure said it will continue engaging with regulators to determine the next development steps. Management stated that discussions will focus on potential Phase III trial design and requirements.
The company said it believes existing data support continued dialogue with regulators. It also cited the durability of results observed in earlier studies.
Analysts noted that conducting a new controlled study would extend development timelines. Additional trial costs may also be required before seeking approval.
The company will request a follow-up meeting with the FDA in the second quarter of 2026. Discussions are expected to focus on pathways for advancing AMT-130 toward a potential future filing.
uniQure confirmed it remains committed to advancing the gene therapy program despite the regulatory setback. Further updates are expected after additional meetings with regulators later this year.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
